# Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Study · id `cardio:ct-nct01551173` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01551173](<https://clinicaltrials.gov/study/NCT01551173>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01551173

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 436 participants.

## Technical summary

Registry record NCT01551173. Randomized; double masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2013-05 (actual). Results posted on 2014-06-11.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 436 participants (enrolled count; ClinicalTrials.gov record NCT01551173, source copy `cardio:ctgov-nct01551173-2015-08-13`, retrieved 2026-10-31)
- Start date: 2012-01 (registry gives no type) (ClinicalTrials.gov record NCT01551173, source copy `cardio:ctgov-nct01551173-2015-08-13`, retrieved 2026-10-31)
- Primary completion: 2013-05 (actual) (ClinicalTrials.gov record NCT01551173, source copy `cardio:ctgov-nct01551173-2015-08-13`, retrieved 2026-10-31)
- Completion: 2013-05 (actual) (ClinicalTrials.gov record NCT01551173, source copy `cardio:ctgov-nct01551173-2015-08-13`, retrieved 2026-10-31)
- Results first posted: 2014-06-11 (ClinicalTrials.gov record NCT01551173, source copy `cardio:ctgov-nct01551173-2015-08-13`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT01551173, source copy `cardio:ctgov-nct01551173-2015-08-13`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01551173-2015-08-13`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
- Condition: Lipid Metabolism Disorders
- Intervention (Drug): Fluvastatin sodium
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 62af8da1a0691b30550b05e79438e00206ea3b12dbf8d406a60295e890b278fe
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
